Biohaven Ltd. reported a third-quarter net loss of $129.3 million, or $0.86 per share, compared to a $173.4 million loss in the prior year period. The company announced significant strategic partnerships, including an exclusive global license with SK Biopharmaceuticals for its Kv7 ion channel platform that provides $400 million in near-term cash consideration upon closing, and an exclusive regional license with Ono Pharmaceutical for its MoDE IgG degrader portfolio, yielding up to $100 million in near-term payments. Additionally, the FDA accepted the resubmission of Biohaven's new drug application for Vyglxia (troriluzole) in spinocerebellar ataxia, setting a user fee goal date in the first quarter of 2027. The company operates as a global clinical-stage biopharmaceutical firm focused on discovering and developing therapies for rare and common diseases.
